Is ACRV or ALLR more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Allarity Therapeutics N/A -109.94% -47.27%

Do analysts prefer ALLR or EXOZ?

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 776.07%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allarity Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALLR or EXOZ more profitable?

Allarity Therapeutics' return on equity of -109.94% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% eXoZymes N/A -220.63% -141.26%

Is MCRB or ALLR more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Allarity Therapeutics N/A -109.94% -47.27%

Do analysts rate BYSI or ALLR?

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 776.07%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BYSI or ALLR more profitable?

BeyondSpring's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Allarity Therapeutics N/A -109.94% -47.27%

Allarity Therapeutics (ALLR) Competitors

$1.17 -0.02 (-1.68%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.01 (+1.20%)

As of 08:31 AM Eastern

Compare

ALLR vs. ACRV, HYFT, EXOZ, MCRB, and BYSI

Should you buy Allarity Therapeutics stock or one of its competitors? MarketBeat compares Allarity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allarity Therapeutics include Acrivon Therapeutics (ACRV), MindWalk (HYFT), eXoZymes (EXOZ), Seres Therapeutics (MCRB), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Allarity Therapeutics compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Allarity Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Allarity Therapeutics	$320K	58.17	-$11.23M	-$0.72	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Acrivon Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Acrivon Therapeutics' return on equity of -64.43% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Allarity Therapeutics	N/A	-109.94%	-47.27%

Acrivon Therapeutics currently has a consensus target price of $11.67, indicating a potential upside of 570.50%. Allarity Therapeutics has a consensus target price of $10.25, indicating a potential upside of 776.07%. Given Allarity Therapeutics' higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 1 mentions for Acrivon Therapeutics and 0 mentions for Allarity Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Acrivon Therapeutics	Neutral
Allarity Therapeutics	Neutral

Summary

Acrivon Therapeutics beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Allarity Therapeutics compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, MindWalk's average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Overall Sentiment
MindWalk	Neutral
Allarity Therapeutics	Neutral

MindWalk presently has a consensus price target of $5.00, suggesting a potential upside of 249.65%. Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 776.07%. Given Allarity Therapeutics' higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allarity Therapeutics has lower revenue, but higher earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	3.80	-$21.69M	-$0.20	N/A
Allarity Therapeutics	$320K	58.17	-$11.23M	-$0.72	N/A

MindWalk has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Allarity Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Allarity Therapeutics	N/A	-109.94%	-47.27%

Summary

MindWalk beats Allarity Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Allarity Therapeutics compare to eXoZymes?

Allarity Therapeutics (NASDAQ:ALLR) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 776.07%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allarity Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.5% of Allarity Therapeutics shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Allarity Therapeutics' return on equity of -109.94% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
eXoZymes	N/A	-220.63%	-141.26%

In the previous week, eXoZymes had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
eXoZymes	Neutral

Allarity Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.73, indicating that its share price is 173% more volatile than the broader market.

eXoZymes has lower revenue, but higher earnings than Allarity Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	58.17	-$11.23M	-$0.72	N/A
eXoZymes	$70K	736.80	-$9.16M	-$1.14	N/A

Summary

Allarity Therapeutics beats eXoZymes on 9 of the 14 factors compared between the two stocks.

How does Allarity Therapeutics compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Seres Therapeutics has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$1.15M	43.14	$5.70M	-$5.17	N/A
Allarity Therapeutics	$320K	58.17	-$11.23M	-$0.72	N/A

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 232.68%. Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 776.07%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Seres Therapeutics' average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Allarity Therapeutics	Neutral

Allarity Therapeutics' return on equity of -109.94% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Allarity Therapeutics	N/A	-109.94%	-47.27%

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Seres Therapeutics has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Summary

Seres Therapeutics beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Allarity Therapeutics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
Allarity Therapeutics	Neutral

BeyondSpring's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Allarity Therapeutics	N/A	-109.94%	-47.27%

BeyondSpring has higher revenue and earnings than Allarity Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	29.14	-$1.01M	-$0.14	N/A
Allarity Therapeutics	$320K	58.17	-$11.23M	-$0.72	N/A

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 776.07%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BeyondSpring has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

BeyondSpring beats Allarity Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Allarity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLR vs. The Competition

Export

Metric	Allarity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.93M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.62	20.49	27.07	23.95
Price / Sales	58.17	300.33	515.72	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.92	7.92	10.62	6.14
Net Income	-$11.23M	$23.81M	$3.60B	$331.74M
7 Day Performance	0.86%	-1.09%	-1.26%	-1.82%
1 Month Performance	-18.18%	2.56%	1.07%	-1.45%
1 Year Performance	20.16%	42.16%	23.63%	16.32%

Allarity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLR Allarity Therapeutics	1.808 of 5 stars	$1.17 -1.7%	$10.25 +776.1%	+17.4%	$18.93M	$320K	N/A	10
ACRV Acrivon Therapeutics	1.615 of 5 stars	$1.86 +4.5%	$11.67 +527.2%	+28.9%	$76.19M	N/A	N/A	58	News Coverage
HYFT MindWalk	2.4725 of 5 stars	$1.51 -7.9%	$5.00 +231.1%	N/A	$75.70M	$17.59M	N/A	80	Analyst Forecast
EXOZ eXoZymes	0.1218 of 5 stars	$7.59 -6.8%	N/A	-39.5%	$74.97M	$70K	N/A	29	Positive News
MCRB Seres Therapeutics	2.6937 of 5 stars	$8.14 +5.6%	$17.00 +108.8%	-63.7%	$74.66M	$790K	N/A	330

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allarity Therapeutics (ALLR) Competitors

ALLR vs. ACRV, HYFT, EXOZ, MCRB, and BYSI

How does Allarity Therapeutics compare to Acrivon Therapeutics?

Summary

How does Allarity Therapeutics compare to MindWalk?

Summary

How does Allarity Therapeutics compare to eXoZymes?

Summary

How does Allarity Therapeutics compare to Seres Therapeutics?

Summary

How does Allarity Therapeutics compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allarity Therapeutics (ALLR) Competitors

ALLR vs. ACRV, HYFT, EXOZ, MCRB, and BYSI

How does Allarity Therapeutics compare to Acrivon Therapeutics?

Which has higher earnings and valuation, ACRV or ALLR?

Do insiders & institutionals believe in ACRV or ALLR?

Which has more risk & volatility, ACRV or ALLR?

Is ACRV or ALLR more profitable?

Do analysts rate ACRV or ALLR?

Does the media refer more to ACRV or ALLR?

Summary

How does Allarity Therapeutics compare to MindWalk?

Does the media refer more to HYFT or ALLR?

Do analysts prefer HYFT or ALLR?

Which has stronger earnings & valuation, HYFT or ALLR?

Which has more volatility & risk, HYFT or ALLR?

Do insiders & institutionals have more ownership in HYFT or ALLR?

Is HYFT or ALLR more profitable?

Summary

How does Allarity Therapeutics compare to eXoZymes?

Do analysts prefer ALLR or EXOZ?

Do institutionals and insiders believe in ALLR or EXOZ?

Is ALLR or EXOZ more profitable?

Does the media favor ALLR or EXOZ?

Which has more risk and volatility, ALLR or EXOZ?

Which has higher valuation and earnings, ALLR or EXOZ?

Summary

How does Allarity Therapeutics compare to Seres Therapeutics?

Which has preferable valuation and earnings, MCRB or ALLR?

Do analysts prefer MCRB or ALLR?

Does the media refer more to MCRB or ALLR?

Is MCRB or ALLR more profitable?

Do institutionals & insiders hold more shares of MCRB or ALLR?

Which has more risk & volatility, MCRB or ALLR?

Summary

How does Allarity Therapeutics compare to BeyondSpring?

Does the media refer more to BYSI or ALLR?

Is BYSI or ALLR more profitable?

Which has better valuation and earnings, BYSI or ALLR?

Do analysts rate BYSI or ALLR?

Which has more risk and volatility, BYSI or ALLR?

Do institutionals and insiders have more ownership in BYSI or ALLR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools